## Andrew Mark James Shapiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5370265/publications.pdf

Version: 2024-02-01

165 papers 19,778 citations

59 h-index 138 g-index

168 all docs 168
docs citations

168 times ranked 9757 citing authors

#	Article	IF	CITATIONS
1	Cost-utility analysis of normothermic machine perfusion compared to static cold storage in liver transplantation in the Canadian setting. American Journal of Transplantation, 2022, 22, 541-551.	4.7	26
2	Current Status, Barriers, and Future Directions for Humanized Mouse Models to Evaluate Stem Cell–Based Islet Cell Transplant. Advances in Experimental Medicine and Biology, 2022, , 89-106.	1.6	1
3	Reassessment of the embryonic fusion plane between the ventral and dorsal pancreases in human donors for transplantation. Pancreatology, 2022, , .	1.1	O
4	Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis. JHEP Reports, 2022, 4, 100495.	4.9	10
5	Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes and Endocrinology, the, 2022, 10, 519-532.	11.4	65
6	Optimizing Generation of Stem Cell-Derived Islet Cells. Stem Cell Reviews and Reports, 2022, 18, 2683-2698.	3.8	7
7	Outcomes Following Extrahepatic and Intraportal Pancreatic Islet Transplantation: A Comparative Cohort Study. Transplantation, 2022, 106, 2224-2231.	1.0	12
8	Opportunities and impediments of human pluripotent stem cell-derived islets in the treatment of diabetes. Journal of Immunology and Regenerative Medicine, 2022, 17, 100064.	0.4	2
9	Frequency of Obliteration of the Dorsal and Ventral Ducts of the Pancreas in Islet Transplantation. Digestive Diseases and Sciences, 2021, 66, 218-223.	2.3	1
10	Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation. Endocrine Reviews, 2021, 42, 198-218.	20.1	22
11	The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting. PharmacoEconomics - Open, 2021, 5, 311-318.	1.8	15
12	Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes. Cells, 2021, 10, 278.	4.1	23
13	Clinical islet transplantation: Current progress and new frontiers. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 243-254.	2.6	22
14	Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients. American Journal of Transplantation, 2021, 21, 3714-3724.	4.7	6
15	Update on islet cell transplantation. Current Opinion in Organ Transplantation, 2021, 26, 397-404.	1.6	15
16	Total pancreatectomy with islet cell autotransplantation in a 2-year-old child with hereditary pancreatitis due to a PRSS1 mutation. American Journal of Transplantation, 2021, 21, 3790-3793.	4.7	5
17	Glucose metabolism and pyruvate carboxylase enhance glutathione synthesis and restrict oxidative stress in pancreatic islets. Cell Reports, 2021, 37, 110037.	6.4	21
18	Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) agonists in islet transplantation: Endogenous in vivo regulatory T cell expansion promotes prolonged allograft survival. American Journal of Transplantation, 2021, , .	4.7	11

#	Article	IF	Citations
19	Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Medicine, 2021, 2, 100466.	6.5	126
20	Treating diabetes with islet cell transplantation: Lessons from the Edmonton experience. , 2020, , 671-684.		1
21	Machine Perfusion of the Liver: Applications Beyond Transplantation. Transplantation, 2020, 104, 1804-1812.	1.0	11
22	Addressing organ shortages: progress in donation after circulatory death for liver transplantation. Canadian Journal of Surgery, 2020, 63, E135-E141.	1.2	8
23	Glucose-dependent partitioning of arginine to the urea cycle protects $\hat{I}^2$ -cells from inflammation. Nature Metabolism, 2020, 2, 432-446.	11.9	27
24	Normothermic Preservation of Liver – What Does the Future Hold?. Advances in Experimental Medicine and Biology, 2020, 1288, 13-31.	1.6	3
25	116-OR: Comparison of Pancreas vs. Islet Transplantation Outcomes from a Large Single Center. Diabetes, 2020, 69, .	0.6	9
26	Islet Cell Transplantation., 2019,, 987-1007.		3
27	Transplantation: Pancreatic and Islet Cells. , 2019, , 259-269.		O
28	Transient Cold Storage Prior to Normothermic Liver Perfusion May Facilitate Adoption of a Novel Technology. Liver Transplantation, 2019, 25, 1503-1513.	2.4	63
29	A Backâ€ŧoâ€Base Experience of Human Normothermic Ex Situ Liver Perfusion: Does the Chill Kill?. Liver Transplantation, 2019, 25, 848-858.	2.4	54
30	Oxygen Perfusion (Persufflation) of Human Pancreata Enhances Insulin Secretion and Attenuates Islet Proinflammatory Signaling. Transplantation, 2019, 103, 160-167.	1.0	23
31	Pan-caspase inhibitor F573 mitigates liver ischemia reperfusion injury in a murine model. PLoS ONE, 2019, 14, e0224567.	2.5	6
32	Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. Transplant International, 2019, 32, 163-172.	1.6	20
33	Posttransplant Characterization of Long-term Functional hESC-Derived Pancreatic Endoderm Grafts. Diabetes, 2019, 68, 953-962.	0.6	27
34	BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. American Journal of Transplantation, 2018, 18, 1879-1889.	4.7	15
35	The journey of islet cell transplantation and future development. Islets, 2018, 10, 80-94.	1.8	126
36	A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic $\hat{l}^2$ -Cells. Diabetes, 2018, 67, 385-399.	0.6	41

#	Article	IF	Citations
37	Beta Cell Death by Cell-free DNA and Outcome After Clinical Islet Transplantation. Transplantation, 2018, 102, 978-985.	1.0	40
38	Ex situ liver perfusion: Organ preservation into the future. Transplantation Reviews, 2018, 32, 132-141.	2.9	7
39	An engineered cell sheet composed of human islets and human fibroblast, bone marrow–derived mesenchymal stem cells, or adipose–derived mesenchymal stem cells: An in vitro comparison study. Islets, 2018, 10, e1445948.	1.8	17
40	Invited Commentary on "Imaging of Intestinal and Multivisceral Transplantation― Radiographics, 2018, 38, 432-434.	3.3	0
41	Islet Cell Transplantation. , 2018, , 181-196.		O
42	Improved islet recovery and efficacy through co-culture and co-transplantation of islets with human adipose-derived mesenchymal stem cells. PLoS ONE, 2018, 13, e0206449.	2.5	49
43	Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead. Advances in Experimental Medicine and Biology, 2018, 1144, 25-35.	1.6	30
44	Ferroptosis-inducing agents compromise in vitro human islet viability and function. Cell Death and Disease, 2018, 9, 595.	6.3	106
45	Clinical islet transplantation: is the future finally now?. Current Opinion in Organ Transplantation, 2018, 23, 428-439.	1.6	60
46	Normothermic ex-vivo liver perfusion: where do we stand and where to reach?. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1045-1058.	3.0	11
47	Circumportal pancreas accompanied with pancreas divisum in a deceased donor for islet transplantation. Surgical and Radiologic Anatomy, 2018, 40, 1323-1325.	1.2	3
48	Engraftment Site and Effectiveness of the Pan-Caspase Inhibitor F573 to Improve Engraftment in Mouse and Human Islet Transplantation in Mice. Transplantation, 2017, 101, 2321-2329.	1.0	20
49	Transplantation of Human Pancreatic Endoderm Cells Reverses Diabetes Post Transplantation in a Prevascularized Subcutaneous Site. Stem Cell Reports, 2017, 8, 1689-1700.	4.8	68
50	Low energy X-ray (grenz ray) treatment of purified islets prior to allotransplant markedly decreases passenger leukocyte populations. Islets, 2017, 9, e1330742.	1.8	1
51	Clinical pancreatic islet transplantation. Nature Reviews Endocrinology, 2017, 13, 268-277.	9.6	525
52	Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma. Journal of Surgical Case Reports, 2016, 2016, rjw188.	0.4	8
53	Harnessing the Foreign Body Reaction in Marginal Mass Device-less Subcutaneous Islet Transplantation in Mice. Transplantation, 2016, 100, 1474-1479.	1.0	36
54	Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care, 2016, 39, 1230-1240.	8.6	498

#	Article	IF	Citations
55	Total pancreatectomy and autoislet transplant for chronic recurrent pancreatitis in a 5-year-old boy. Journal of Pediatric Surgery Case Reports, 2016, 13, 28-30.	0.2	1
56	A Multicenter Study: North American Islet Donor Score in Donor Pancreas Selection for Human Islet Isolation for Transplantation. Cell Transplantation, 2016, 25, 1515-1523.	2.5	42
57	National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes, 2016, 65, 3418-3428.	0.6	143
58	Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors. Transplant International, 2016, 29, 34-40.	1.6	28
59	Long-term function and optimization of mouse and human islet transplantation in the subcutaneous device-less site. Islets, 2016, 8, 186-194.	1.8	25
60	Reparixin, a CXCR1/2 inhibitor in islet allotransplantation. Islets, 2016, 8, 115-124.	1.8	23
61	A novel redox-active metalloporphyrin reduces reactive oxygen species and inflammatory markers but does not improve marginal mass engraftment in a murine donation after circulatory death islet transplantation model. Islets, 2016, 8, e1190058.	1.8	13
62	Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. Diabetes, 2016, 65, 451-462.	0.6	23
63	Lung-Derived Microscaffolds Facilitate Diabetes Reversal after Mouse and Human Intraperitoneal Islet Transplantation. PLoS ONE, 2016, 11, e0156053.	2.5	34
64	Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Transplantation, 2015, 99, 2294-2300.	1.0	97
65	Islet Transplantation for Type 1 Diabetes. Juntendo Medical Journal, 2015, 61, 131-135.	0.1	О
66	Bioengineered stem cells as an alternative for islet cell transplantation. World Journal of Transplantation, 2015, 5, 1.	1.6	18
67	A prevascularized subcutaneous device-less site for islet and cellular transplantation. Nature Biotechnology, 2015, 33, 518-523.	17.5	293
68	Impact of adverse pancreatic injury at surgical procurement upon islet isolation outcome. Transplant International, 2014, 27, 1135-1142.	1.6	12
69	Research Productivity of Residents and Surgeons With Formal Research Training. Journal of Surgical Education, 2014, 71, 865-870.	2.5	35
70	Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 211.	2.4	123
71	Single-Donor Islet Transplantation and Long-term Insulin Independence in Select Patients With Type 1 Diabetes Mellitus. Transplantation, 2014, 98, 1007-1012.	1.0	55
72	Islet cell transplantation. Seminars in Pediatric Surgery, 2014, 23, 83-90.	1.1	29

#	Article	IF	CITATIONS
73	Pancreas Versus Islets After a Successful Kidney Transplant. Current Transplantation Reports, 2014, 1, 124-135.	2.0	3
74	Biologic Agents in Islet Transplantation. Current Diabetes Reports, 2013, 13, 713-722.	4.2	25
75	Glutathione Ethyl Ester Supplementation during Pancreatic Islet Isolation Improves Viability and Transplant Outcomes in a Murine Marginal Islet Mass Model. PLoS ONE, 2013, 8, e55288.	2.5	20
76	Immune Antibody Monitoring Predicts Outcome in Islet Transplantation. Diabetes, 2013, 62, 1377-1378.	0.6	10
77	Clinical islet isolation outcomes with a highly purified neutral protease for pancreas dissociation. Islets, 2013, 5, 111-115.	1.8	13
78	Microbial Contamination of Clinical Islet Transplant Preparations Is Associated with Very Low Risk of Infection. Diabetes Technology and Therapeutics, 2013, 15, 323-327.	4.4	27
79	Long-term follow-up of hepatic ultrasound findings in subjects with magnetic resonance imaging defined hepatic steatosis following clinical islet transplantation. Islets, 2013, 5, 16-21.	1.8	12
80	Humoral Immune Response following Seasonal Influenza Vaccine in Islet Transplant Recipients. Cell Transplantation, 2013, 22, 469-476.	2.5	5
81	Current status of clinical islet transplantation. World Journal of Transplantation, 2013, 3, 48.	1.6	56
82	Revascularization of Transplanted Pancreatic Islets and Role of the Transplantation Site. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	124
83	Islet Transplantation in Type 1 Diabetes: Ongoing Challenges, Refined Procedures, and Long-Term Outcome. Review of Diabetic Studies, 2012, 9, 385-406.	1.3	92
84	Update on Islet Transplantation. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007823-a007823.	6.2	179
85	Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010. Diabetes Care, 2012, 35, 1436-1445.	8.6	665
86	Human Mesenchymal Stem Cells Protect Human Islets from Pro-Inflammatory Cytokines. PLoS ONE, 2012, 7, e38189.	2.5	112
87	Caspase Inhibitor IDN6556 Facilitates Marginal Mass Islet Engraftment in a Porcine Islet Autotransplant Model. Transplantation, 2012, 94, 30-35.	1.0	13
88	A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 281-288.	2.6	44
89	Intra-abdominal adhesions: Cellular mechanisms and strategies for prevention. International Journal of Surgery, 2011, 9, 589-594.	2.7	110
90	The Impact of Sirolimus on hepatitis C Recurrence after Liver Transplantation. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 28-34.	1.7	42

#	Article	IF	CITATIONS
91	The Risk to Human Islet Cell Transplant Recipients of Acquiring Variant Creutzfeldt-Jakob Disease: A Provisional Quantitative Risk Assessment. Transplantation, 2011, 92, e2-e4.	1.0	6
92	The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery, 2011, 150, 48-55.	1.9	35
93	State of the Art of Clinical Islet Transplantation and Novel Protocols of Immunosuppression. Current Diabetes Reports, 2011, 11, 345-354.	4.2	124
94	AEB071 (sotrastaurin) does not exhibit toxic effects on human islets in vitro nor after transplantation into immunodeficient mice. Islets, 2011, 3, 338-343.	1.8	3
95	Strategies toward single-donor islets of Langerhans transplantation. Current Opinion in Organ Transplantation, 2011, 16, 627-631.	1.6	84
96	Insulin-Heparin Infusions Peritransplant Substantially Improve Single-Donor Clinical Islet Transplant Success. Transplantation, 2010, 89, 465-471.	1.0	108
97	Comparison of Human Islet Isolation Outcomes Using a New Mammalian Tissue-Free Enzyme Versus Collagenase NB-1. Transplantation, 2010, 90, 255-259.	1.0	50
98	Are stem cells a cure for diabetes?. Clinical Science, 2010, 118, 87-97.	4.3	49
99	Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology, 2010, 51, 1237-1243.	7.3	281
100	Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transplant International, 2010, 23, 259-265.	1.6	71
101	Caspase Inhibitor Therapy Synergizes With Costimulation Blockade to Promote Indefinite Islet Allograft Survival. Diabetes, 2010, 59, 1469-1477.	0.6	19
102	Experience of islet isolation without neutral protease supplementation. Islets, 2010, 2, 278-282.	1.8	14
103	Surgical aspects of human islet isolation. Islets, 2010, 2, 265-273.	1.8	40
104	Role of Imaging in Clinical Islet Transplantation. Radiographics, 2010, 30, 353-366.	3.3	54
105	Porcine Marginal Mass Islet Autografts Resist Metabolic Failure Over Time and Are Enhanced by Early Treatment with Liraglutide. Endocrinology, 2009, 150, 2145-2152.	2.8	36
106	BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. Journal of Leukocyte Biology, 2009, 86, 41-51.	3.3	28
107	Circumportal pancreas and islet isolation. Surgery, 2009, 146, 126-127.	1.9	10
108	Portal Vein Embolization with Radiolabeled Polyvinyl Alcohol Particles in a Swine Model: Hepatic Distribution and Implications for Pancreatic Islet Cell Transplantation. CardioVascular and Interventional Radiology, 2009, 32, 499-507.	2.0	7

#	Article	IF	CITATIONS
109	Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transplant International, 2009, 22, 182-191.	1.6	48
110	High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transplant International, 2009, 22, 622-625.	1.6	31
111	Histologic Graft Assessment After Clinical Islet Transplantation. Transplantation, 2009, 88, 1286-1293.	1.0	74
112	Protein Kinase C Inhibitor, AEB-071, Acts Complementarily With Cyclosporine to Prevent Islet Rejection in Rats. Transplantation, 2009, 87, 59-65.	1.0	12
113	Nonsimultaneous Administration of Pancreas Dissociation Enzymes During Islet Isolation. Transplantation, 2009, 87, 1700-1705.	1.0	24
114	The Use of an Approved Biodegradable Polymer Scaffold as a Solid Support System for Improvement of Islet Engraftment. Artificial Organs, 2008, 32, 990-993.	1.9	35
115	Risk factors for islet loss during culture prior to transplantation. Transplant International, 2008, 21, 1029-35.	1.6	109
116	Islet transplantationâ€"the imperative need for continued clinical trials. Nature Clinical Practice Nephrology, 2008, 4, 662-663.	2.0	9
117	The Caspase Selective Inhibitor EP1013 Augments Human Islet Graft Function and Longevity in Marginal Mass Islet Transplantation in Mice. Diabetes, 2008, 57, 1556-1566.	0.6	55
118	The Impact of Preoperative Endoscopic Ultrasound on the Surgical Management of Pancreatic Neuroendocrine Tumours. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 817-820.	1.7	20
119	Caspase Inhibitor Therapy Enhances Marginal Mass Islet Graft Survival and Preserves Long-Term Function in Islet Transplantation. Diabetes, 2007, 56, 1289-1298.	0.6	64
120	Negative and Positive Co-Signaling With Anti-BTLA (PJ196) and CTLA4lg Prolongs Islet Allograft Survival. Transplantation, 2007, 84, 1368-1372.	1.0	26
121	Factors Influencing the Collagenase Digestion Phase of Human Islet Isolation. Transplantation, 2007, 83, 7-12.	1.0	64
122	Quality of Life After Islet Transplant: Impact of the Number of Islet Infusions and Metabolic Outcome. Transplantation, 2007, 84, 664-666.	1.0	50
123	Factors Influencing the Loss of $\hat{l}^2$ -Cell Mass in Islet Transplantation. Cell Transplantation, 2007, 16, 1-8.	2.5	144
124	Enhancing the Success of Human Islet Isolation Through Optimization and Characterization of Pancreas Dissociation Enzyme. American Journal of Transplantation, 2007, 7, 1233-1241.	4.7	62
125	Progress in Islet Transplantation in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 147-158.	1.8	8
126	International Trial of the Edmonton Protocol for Islet Transplantation. New England Journal of Medicine, 2006, 355, 1318-1330.	27.0	1,754

#	Article	IF	CITATIONS
127	Interventional Strategies to Prevent Â-Cell Apoptosis in Islet Transplantation. Diabetes, 2006, 55, 1907-1914.	0.6	131
128	Current status of pancreatic islet transplantation. Clinical Science, 2006, 110, 611-625.	4.3	118
129	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. Cell Transplantation, 2006, 15, 105-119.	2.5	65
130	Current indications for pancreas or islet transplant. Diabetes, Obesity and Metabolism, 2006, 8, 1-7.	4.4	79
131	Current Status of Clinical Islet Cell Transplantation. , 2006, 333, 47-104.		59
132	Strategic Opportunities in Clinical Islet Transplantation. Transplantation, 2005, 79, 1304-1307.	1.0	121
133	Pancreas Divisum: A Study of the Cadaveric Donor Pancreas for Islet Isolation. Pancreas, 2005, 30, 325-327.	1.1	32
134	The Portal Immunosuppressive Storm. Therapeutic Drug Monitoring, 2005, 27, 35-37.	2.0	117
135	XIAP Overexpression in Islet beta-Cells Enhances Engraftment and Minimizes Hypoxia-Reperfusion Injury. American Journal of Transplantation, 2005, 5, 1297-1305.	4.7	51
136	Proteinuria Developing After Clinical Islet Transplantation Resolves with Sirolimus Withdrawal and Increased Tacrolimus Dosing. American Journal of Transplantation, 2005, 5, 2318-2323.	4.7	90
137	Sirolimus-Induced Ulceration of the Small Bowel in Islet Transplant Recipients: Report of Two Cases. American Journal of Transplantation, 2005, 5, 2799-2804.	4.7	50
138	Prevention of Bleeding After Islet Transplantation: Lessons Learned from a Multivariate Analysis of 132 Cases at a Single Institution. American Journal of Transplantation, 2005, 5, 2992-2998.	4.7	137
139	Five-Year Follow-Up After Clinical Islet Transplantation. Diabetes, 2005, 54, 2060-2069.	0.6	1,489
140	XIAP Overexpression in Human Islets Prevents Early Posttransplant Apoptosis and Reduces the Islet Mass Needed to Treat Diabetes. Diabetes, 2005, 54, 2541-2548.	0.6	102
141	Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet, The, 2005, 365, 1642-1644.	13.7	216
142	Assessment of the Severity of Hypoglycemia and Glycemic Lability in Type 1 Diabetic Subjects Undergoing Islet Transplantation. Diabetes, 2004, 53, 955-962.	0.6	315
143	Multiple Combination Therapies Involving Blockade of ICOS/B7RP-1 Costimulation Facilitate Long-Term Islet Allograft Survival. American Journal of Transplantation, 2004, 4, 526-536.	4.7	68
144	Unraveling the Secrets of Single Donor Success in Islet Transplantation. American Journal of Transplantation, 2004, 4, 295-298.	4.7	60

#	Article	IF	CITATIONS
145	Risks and side effects of islet transplantation. Current Diabetes Reports, 2004, 4, 304-309.	4.2	108
146	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation, 2004, 10, 1301-1311.	2.4	241
147	Islet Transplantation in Patients with Diabetes Mellitus. BioDrugs, 2004, 18, 315-328.	4.6	58
148	Magnetic Resonance-Defined Perinephric Edema After Clinical Islet Transplantation: A Benign Finding Associated with Mild Renal Impairment. Transplantation, 2004, 78, 945-948.	1.0	7
149	Prevalence of Hepatic Steatosis After Islet Transplantation and Its Relation to Graft Function. Diabetes, 2004, 53, 1311-1317.	0.6	148
150	Clinical islet transplant: current and future directions towards tolerance. Immunological Reviews, 2003, 196, 219-236.	6.0	73
151	Cell encapsulation: Promise and progress. Nature Medicine, 2003, 9, 104-107.	30.7	546
152	Technical aspects of islet preparation and transplantation. Transplant International, 2003, 16, 613-632.	1.6	89
153	Edmonton's islet success has indeed been replicated elsewhere. Lancet, The, 2003, 362, 1242.	13.7	158
154	Percutaneous Transhepatic Pancreatic Islet Cell Transplantation in Type 1 Diabetes Mellitus: Radiologic Aspects. Radiology, 2003, 229, 165-170.	<b>7.</b> 3	120
155	Changes in liver enzymes after clinical islet transplantation1. Transplantation, 2003, 76, 1280-1284.	1.0	60
156	Technical aspects of islet preparation and transplantation. Transplant International, 2003, 16, 613-632.	1.6	41
157	Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation, 2002, 74, 1687-1691.	1.0	113
158	Preservation of the human pancreas before islet isolation using a two-layer (UW) Tj ETQq0 0 0 rgBT /Overlock 10	) Tf 50 222 1.0	? Tg <sub>9</sub> (solution
159	Portal venous pressure changes after sequential clinical islet transplantation. Transplantation, 2002, 74, 913-915.	1.0	131
160	Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. Transplantation, 2002, 74, 1522-1528.	1.0	27
161	Successful Islet Transplantation: Continued Insulin Reserve Provides Long-Term Glycemic Control. Diabetes, 2002, 51, 2148-2157.	0.6	701
162	Islet cell transplantation. Lancet, The, 2001, 358, S21.	13.7	56

#	Article	IF	CITATIONS
163	Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen. New England Journal of Medicine, 2000, 343, 230-238.	27.0	4,772
164	Intraductal Collagenase Delivery into the Human Pancreas Using Syringe Loading or Controlled Perfusion. Cell Transplantation, 1999, 8, 285-292.	2.5	195
165	VARIABLES IN ORGAN DONORS THAT AFFECT THE RECOVERY OF HUMAN ISLETS OF LANGERHANS1. Transplantation, 1996, 61, 1047-1053.	1.0	280